These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 33926921

  • 1. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Nabi H, Georgiadis S, Loft AG, Hendricks O, Jensen DV, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B.
    Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R, Castellani C, Mancuso S, Sciarra G, Giardina F, Bevignani G, Ceccarelli F, Spinelli FR, Alessandri C, Di Franco M, Riccieri V, Priori R, Conti F.
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C, Bitti R, Nacci F, Cometi L, Tofani L, Bartoli F, Fiori G, Matucci-Cerinic M.
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [Abstract] [Full Text] [Related]

  • 4. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
    Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML.
    Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
    Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B.
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X, Hu R, Peng L, Liu M, Sun Z.
    Front Immunol; 2021 Nov; 12():638444. PubMed ID: 33889152
    [Abstract] [Full Text] [Related]

  • 10. SB5: An Adalimumab Biosimilar.
    Frampton JE.
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [Abstract] [Full Text] [Related]

  • 11. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, Ajgeiy KK, Iversen L, Skov L.
    JAMA Dermatol; 2021 Jun 01; 157(6):676-683. PubMed ID: 33825804
    [Abstract] [Full Text] [Related]

  • 12. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S, Chadwick L, Mysler E, Moots RJ.
    Curr Rheumatol Rep; 2018 Aug 09; 20(10):57. PubMed ID: 30094742
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Bjørner JB, Hetland ML.
    Arthritis Rheumatol; 2019 Dec 09; 71(12):1997-2004. PubMed ID: 31268624
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, Quartuccio L, Egan CG, Lo Monaco A, Benucci M, Salaffi F, Semeraro A, Parisi S, Ceccarelli F, Piazza I, Foti R.
    Rheumatol Int; 2020 Feb 09; 40(2):263-272. PubMed ID: 31435754
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Cheong SY, Ghil J.
    Arthritis Rheumatol; 2018 Jan 09; 70(1):40-48. PubMed ID: 28950421
    [Abstract] [Full Text] [Related]

  • 19. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
    Kearsley-Fleet L, Baildam E, Beresford MW, Douglas S, Foster HE, Southwood TR, Hyrich KL, UK JIA Biologics Register.
    Lancet Rheumatol; 2024 Jul 09; 6(7):e438-e446. PubMed ID: 38843858
    [Abstract] [Full Text] [Related]

  • 20. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
    Melville AR, Md Yusof MY, Fitton J, Garcia-Montoya L, Bailey L, Dass S, Emery P, Buch MH, Saleem B.
    Rheumatology (Oxford); 2021 Aug 02; 60(8):3679-3688. PubMed ID: 33432358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.